CME Group
CME
$293.87
+1.52%
CME Group Inc. operates the world's largest derivatives marketplace, providing trading and clearing services for futures and options contracts across interest rates, equity indexes, foreign currencies, energy, metals, and agricultural commodities, while also generating revenue from market data and clearing services. As the dominant exchange operator in its space, CME holds a structural moat built on deep liquidity, network effects, and its exclusive license to trade and clear S&P futures through its 27% stake in S&P Dow Jones Indices, making it the go-to venue for institutional hedging and price discovery. The current investor narrative centers on the durability of trading volumes against a backdrop of a hawkish Federal Reserve under Chair Kevin Warsh, where rising odds of multiple rate hikes through 2027 are simultaneously a potential volume tailwind for interest-rate hedging and a valuation headwind for high-multiple financials. Debate is further shaped by a mixed analyst stance, with several firms recently downgrading to Hold or maintaining Underweight/Underperform ratings even as the stock has rebounded sharply from its mid-year trough, leaving investors to weigh resilient clearing-fee economics against a rich multiple and slowing headline revenue growth.…
CME
CME Group
$293.87
Related headlines
Investment Opinion: Should I buy CME Today?
The synthesized recommendation is Hold. CME's structural moat, elite margins, and defensive profile justify a premium valuation, but stagnant revenue growth and a fair-to-rich multiple limit upside. The analyst consensus rating of 'hold' with an average target of $292.94 (0.3% downside) reinforces this view, suggesting the stock is fully valued after its recent rally.
Supporting evidence includes a 62.0% net margin and 86.1% gross margin, which are best-in-class and support the quality premium. However, revenue growth of 0.84% YoY is anemic, and the forward PE of 22.6x offers only a 7.4% discount to trailing, implying modest earnings growth expectations. Free cash flow of $4.213 billion TTM is robust, but the 97.2% payout ratio limits dividend growth. The stock's 19.9% three-month gain has outpaced the S&P 500 by 17.2 percentage points, likely pricing in near-term optimism.
Key risks include a potential volume slowdown if volatility normalizes, multiple compression if growth remains weak, and thin dividend coverage. The rating would upgrade to Buy if revenue growth accelerates above 5% or if the PE compresses below 20x, and downgrade to Sell if revenue declines or if the payout ratio exceeds 100%. Relative to its historical PE range of 18.7x-32.8x, the current 24.4x is mid-range, suggesting the stock is fairly valued, not undervalued.
Sign up to view all
CME 12-Month Price Forecast
CME is a high-quality franchise with a wide moat and exceptional margins, but its growth has stalled, and the stock appears fairly valued. The balance of risks is balanced: potential volume tailwinds from Fed hikes are offset by valuation compression risk. We would upgrade to bullish if revenue growth accelerates above 5% or if the stock pulls back to the low $250s, and downgrade to bearish if revenue declines or if the payout ratio exceeds 100%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CME Group's 12-month outlook, with a consensus price target around $292.94 and implied upside of -0.3% versus the current price.
Average Target
$292.94
0 analysts
Implied Upside
-0.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$218 - $337
Analyst target range
Coverage is solid with 16 analysts, but sentiment is decidedly lukewarm: the consensus recommendation is "hold" with a mean rating of 2.53 on a scale where lower is more bullish. The average target price of $292.94 sits essentially at the current $293.87 price, implying roughly -0.3% downside — a signal that the Street views the stock as fully valued after its 19.9% three-month rally. The consensus leans neutral-to-cautious, and the estimated EPS average of $16.80 against a forward PE of 22.6x suggests analysts are not modeling meaningful earnings acceleration.
The target range of $218.00 to $337.00 is wide, spanning a 54% spread from low to high, which signals genuine disagreement about the trajectory of trading volumes and the rate environment. The high target of $337 assumes a breakout above the 52-week high, likely predicated on a volatility-driven volume surge from Fed tightening and multiple expansion toward the top of the historical PE band. The low target of $218 essentially prices in a return to the June lows — margin pressure from normalized volatility and a de-rating of the premium multiple. Recent institutional actions skew cautious: Deutsche Bank downgraded to Hold from Buy in August 2026, while JP Morgan and B of A maintain Underweight and Underperform ratings, offset only by TD Cowen, Morgan Stanley, and Piper Sandler staying constructive — a split that reinforces the hold consensus and suggests limited near-term catalyst for multiple expansion.
Drowning in data?
Find the real signal!
Bulls vs Bears: CME Investment Factors
The bull case rests on CME's unmatched moat, elite margins, and defensive characteristics, while the bear case highlights stagnant revenue, a rich multiple, and cautious analyst sentiment. Currently, the bear evidence appears slightly stronger given the 0.84% revenue growth and the stock trading at fair value per analyst targets. The most critical tension is whether Fed rate hikes will spur a volume surge that accelerates revenue growth, or whether the stock's premium valuation will compress as growth remains elusive. Resolution of this debate will likely determine the stock's direction over the next year.
Bullish
- Structural moat and network effects: CME operates the world's largest derivatives marketplace with deep liquidity and exclusive rights to trade and clear S&P futures through its 27% stake in S&P Dow Jones Indices. This creates high barriers to entry and pricing power, evidenced by a 62.0% net margin and 86.1% gross margin.
- Elite profitability and cash generation: Q2 2026 net income was $1.042 billion on a 61.1% net margin, with operating margin of 64.9%. Free cash flow TTM is $4.213 billion, funding $468.1 million in dividends and $698.2 million in buybacks in the quarter.
- Fortress balance sheet with low leverage: Debt-to-equity is just 0.119 and the current ratio is 1.03, indicating minimal financial risk. This allows CME to return capital aggressively while maintaining investment-grade stability.
- Defensive low-beta profile: Beta of 0.27 means CME is roughly 73% less volatile than the market, offering portfolio stability. The stock has gained 19.9% over three months, outperforming the S&P 500's 2.69% by 17.2 percentage points, showing strong relative strength.
Bearish
- Stagnant revenue growth: Q2 2026 revenue grew only 0.84% YoY to $1.706 billion, and sequentially declined from $1.880 billion in Q1. Revenue has oscillated in a $1.5-$1.9 billion band, showing no sustained growth trajectory.
- Rich valuation with limited upside: Trailing PE of 24.4x and PS of 15.1x are elevated for a company with near-zero growth. The average analyst target of $292.94 implies -0.3% downside, and the consensus rating is 'hold' with a mean of 2.53.
- Thin dividend coverage: The payout ratio is 97.2%, leaving little room for dividend growth without earnings expansion. The 4.0% dividend yield, while attractive, may be unsustainable if earnings stagnate.
- Recent analyst downgrades and cautious sentiment: Deutsche Bank downgraded to Hold in August 2026, while JP Morgan and B of A maintain Underweight and Underperform ratings. This split reflects concerns about valuation and growth prospects.
CME Technical Analysis
CME is in a recovery uptrend that has largely repaired the damage from a severe mid-year drawdown. The stock is up 11.95% over the trailing year and sits at $293.87, which is approximately 89.3% of its 52-week range of $218.31 to $329.16, placing it in the upper portion of its band but still about 10.7% below the 52-week high. This positioning signals constructive momentum rather than overextension, though the stock has not yet reclaimed its highs, and the -33.05% max drawdown on record underscores how sharp the prior decline was.
Short-term momentum is clearly accelerating and diverging positively from the longer-term trend. The stock has gained 7.86% over the past month and 19.92% over three months, dramatically outpacing the S&P 500's 1.22% and 2.69% respective gains, producing relative strength readings of +6.64 and +17.23. That three-month surge followed a capitulation low near $218 in late June, and the subsequent rally has been persistent, with the most recent session adding 1.52% on volume of roughly 2.18 million shares. The 1-year relative strength of -3.58 versus SPY shows the stock is still playing catch-up on a full-year basis, suggesting the recent outperformance is mean-reversion recovery rather than a new leadership regime.
Key technical levels are well defined: support sits at the 52-week low of $218.31, with intermediate support around the $260-$270 zone that contained the September pullback, while resistance is the 52-week high of $329.16. A breakout above $329 would confirm a full trend reversal and likely invite momentum buyers, whereas a breakdown below $260 would signal the recovery has failed and reopen the June lows. The beta of just 0.27 is a critical risk-management input — CME is roughly 73% less volatile than the market, meaning position sizing can be larger for equivalent risk and the stock offers defensive characteristics that make the recent 19.9% three-month move all the more notable relative to its low-volatility profile.
Beta
0.27
0.27x market volatility
Max Drawdown
-33.0%
Largest decline past year
52-Week Range
$218-$329
Price range past year
Annual Return
+11.9%
Cumulative gain past year
| Period | CME Return | S&P 500 |
|---|---|---|
| 1m | +7.9% | +0.2% |
| 3m | +19.9% | +2.9% |
| 6m | +2.2% | +8.4% |
| 1y | +11.9% | +14.9% |
| ytd | +9.0% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CME Fundamental Analysis
Revenue growth has decelerated to a crawl, with Q2 2026 revenue of $1.706 billion up just 0.84% year over year, a sharp slowdown from the $1.880 billion booked in Q1 2026 and roughly flat versus the $1.692 billion in Q2 2025. The sequential decline from Q1 to Q2 reflects the seasonal and volatility-dependent nature of trading volumes, and the multi-quarter trend shows revenue oscillating in a $1.5-$1.9 billion band rather than compounding. Within the mix, clearing and transaction fees of $1.353 billion dominate at roughly 79% of revenue, with market data at $238.1 million and other revenue at $115.6 million, meaning overall growth is hostage to contract volumes and pricing rather than diversified segment expansion — a structural limitation for the investment case.
Profitability remains elite even as growth stalls. Q2 2026 net income was $1.042 billion on a 61.1% net margin, with gross margin of 69.2% and operating margin of 64.9%, and the trailing valuation data shows a 62.0% net margin and 86.1% gross margin. Margins have been remarkably stable — net margin has hovered between roughly 58% and 71% across the last eight quarters — reflecting the operating leverage of an exchange model where incremental volume carries minimal cost. The Q2 gross margin of 69.2% was lower than Q1's 88.1%, but that gap is largely an accounting artifact of cost-of-revenue classification rather than true margin compression, and the 64.9% operating margin confirms the core economics are intact.
Financial health is exceptional, anchored by a debt-to-equity ratio of just 0.119 and a current ratio of 1.03. Free cash flow is robust at $4.213 billion TTM, with Q2 2026 FCF of $923.5 million against operating cash flow of $947.1 million, and the company returned capital aggressively via $468.1 million in dividends and $698.2 million in buybacks in the quarter. ROE of 14.08% and ROA of 1.48% reflect the capital-light but heavily levered-balance-sheet nature of the business, and the 97.2% payout ratio is a yellow flag — dividend coverage is thin relative to earnings, meaning future dividend growth depends on earnings expansion rather than further payout-ratio increases. The company funds growth and returns internally with no meaningful external financing dependence.
Quarterly Revenue
$1.7B
2026-06
Revenue YoY Growth
+0.8%
YoY Comparison
Gross Margin
69.3%
Latest Quarter
Free Cash Flow
$4.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CME Overvalued?
Because CME is solidly profitable with trailing net income of roughly $4.2 billion, the PE ratio is the appropriate primary metric. The stock trades at a trailing PE of 24.4x versus a forward PE of 22.6x, a modest 7.4% compression that implies the market expects only modest earnings growth — consistent with the 0.84% revenue growth and the $16.80 consensus EPS estimate. The PEG ratio of 1.59 suggests the multiple is reasonably supported by expected growth, though the forward discount is far smaller than what one would expect from a high-growth compounder.
Against its industry, CME's valuation looks stretched on sales-based measures. The PS ratio of 15.1x and EV/Sales of 15.6x are rich for a financial data and exchange business, while the EV/EBITDA of 16.8x and PB of 3.42x are more moderate. The 62.0% net margin and 86.1% gross margin are best-in-class and justify a premium to the sector, but the 15.1x PS multiple leaves little room for the revenue stagnation evident in the 0.84% YoY growth, and the 4.0% dividend yield is unusually high for the group, reflecting a payout that consumes 97.2% of earnings.
Historically, CME's PE has ranged from roughly 18.7x to 32.8x over the past several years, and the current 24.4x trailing multiple sits near the middle of that band — neither a bargain nor a bubble. The PS ratio, however, has ranged from about 45.8x to 71.4x on the historical data, and the current 15.1x reading appears dramatically lower, though this discrepancy likely reflects a change in the share count or revenue base used in the historical calculation rather than a true re-rating. On the more reliable PE basis, the stock is priced for stability rather than growth, and the market appears to be paying a quality premium for CME's defensive, low-beta cash generation rather than discounting an acceleration in volumes.
PE
24.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~28x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on CME's dependence on trading volumes, which are cyclical and sensitive to market volatility. Revenue growth has stalled at 0.84% YoY in Q2 2026, and the 97.2% payout ratio leaves little cushion for dividend growth without earnings expansion. Additionally, the company's high operating leverage means any volume decline could disproportionately impact profits, as seen in the Q2 gross margin drop to 69.2% from 88.1% in Q1, though this was partly an accounting artifact. With debt-to-equity at 0.119, financial leverage is low, but the business remains vulnerable to prolonged low-volatility periods.
Market and competitive risks include valuation compression if growth fails to materialize. The stock trades at 24.4x trailing earnings and 15.1x sales, which is rich for a low-growth company. Beta of 0.27 suggests low correlation with the market, but sector rotation away from defensive names could pressure the multiple. Recent news highlights hawkish Fed policy under Chair Warsh, with rising odds of rate hikes that could increase volatility but also potentially boost trading volumes. However, competitors like CBOE and ICE are also vying for market share, and regulatory changes could impact fee structures. Analyst sentiment is lukewarm, with a consensus hold and recent downgrades, indicating limited near-term catalysts.
Worst-case scenario involves a return to the June 2026 lows of $218.31, representing a 25.7% decline from the current $293.87. This could occur if trading volumes stagnate, Fed hikes fail to stimulate hedging activity, and the premium multiple compresses toward the lower end of its historical PE range (18.7x). The analyst low target of $218 aligns with this level, implying a -25.8% downside. Additionally, a broader market selloff could exacerbate the decline given the stock's recent 19.9% three-month rally, which may have borrowed from future returns.
FAQ
The biggest risk is revenue stagnation, with Q2 2026 growth at just 0.84% YoY, which could lead to multiple compression. Competitive threats from other exchanges like CBOE and ICE could pressure market share and fees. Macro risks include Fed policy uncertainty; while rate hikes could boost volumes, they could also increase market volatility and impact valuation. Company-specific risks include the high payout ratio of 97.2%, which limits dividend growth, and the potential for a volume decline if volatility normalizes. The stock's max drawdown of -33.05% shows it is not immune to sharp declines.
Our 12-month forecast has a base case (50% probability) of $280-$300, assuming stable volumes and no major growth acceleration. The bull case (25%) targets $320-$337 if Fed hikes drive a volume surge and multiple expansion. The bear case (25%) targets $218-$250 if revenue declines and the multiple compresses. The most likely scenario is the base case, as it aligns with the analyst average target and current valuation. Key to the forecast is whether interest-rate hedging activity picks up meaningfully.
CME appears fairly valued. Its trailing PE of 24.4x is in the middle of its historical range of 18.7x-32.8x, and the forward PE of 22.6x suggests modest earnings growth expectations. The PS ratio of 15.1x is high for a low-growth company, but the 62.0% net margin justifies a premium. Compared to peers, CME's valuation is likely at the higher end due to its quality, but the lack of growth limits multiple expansion. The market is paying a fair price for stability, not growth.
CME is a high-quality company with a wide moat and exceptional margins, but at $293.87, it trades near the analyst average target of $292.94, implying limited upside. The stock's 24.4x trailing PE is fair for its growth profile, and the 4.0% dividend yield appeals to income investors. However, revenue growth of 0.84% YoY is a concern, and the 97.2% payout ratio leaves little room for dividend increases. For long-term investors seeking stability and income, CME is a reasonable hold, but for those seeking growth, better opportunities may exist elsewhere. A pullback to the $250s would improve the risk/reward.
CME is better suited for long-term investment due to its defensive characteristics, low beta of 0.27, and consistent dividend. Short-term trading is less attractive given the stock's low volatility and lack of near-term catalysts. The 4.0% dividend yield and strong free cash flow provide a steady return for patient investors. A minimum holding period of 2-3 years is recommended to ride out volume cycles and benefit from potential dividend growth. However, given the current fair valuation, new investors might wait for a better entry point.
